BI Asset Management Fondsmaeglerselskab A S Sells 1,376 Shares of United Therapeutics Corporation $UTHR

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

BI Asset Management Fondsmaeglerselskab A S lowered its position in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 1.6% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 83,866 shares of the biotechnology company's stock after selling 1,376 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S owned approximately 0.19% of United Therapeutics worth $25,853,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Quantbot Technologies LP grew its holdings in United Therapeutics by 5,072.2% during the 1st quarter. Quantbot Technologies LP now owns 1,862 shares of the biotechnology company's stock worth $574,000 after acquiring an additional 1,826 shares during the period. Korea Investment CORP grew its holdings in United Therapeutics by 25.7% during the 1st quarter. Korea Investment CORP now owns 49,389 shares of the biotechnology company's stock worth $15,225,000 after acquiring an additional 10,100 shares during the period. Qtron Investments LLC grew its holdings in United Therapeutics by 131.7% during the 1st quarter. Qtron Investments LLC now owns 1,754 shares of the biotechnology company's stock worth $541,000 after acquiring an additional 997 shares during the period. Brooklyn Investment Group grew its holdings in United Therapeutics by 103.2% during the 1st quarter. Brooklyn Investment Group now owns 193 shares of the biotechnology company's stock worth $59,000 after acquiring an additional 98 shares during the period. Finally, Northwest & Ethical Investments L.P. boosted its holdings in United Therapeutics by 42.0% during the first quarter. Northwest & Ethical Investments L.P. now owns 5,416 shares of the biotechnology company's stock worth $1,670,000 after buying an additional 1,602 shares during the last quarter. Institutional investors own 94.08% of the company's stock.

United Therapeutics Trading Up 0.5%

Shares of United Therapeutics stock traded up $1.57 during trading hours on Friday, reaching $312.23. 576,473 shares of the company's stock were exchanged, compared to its average volume of 525,026. The stock has a market cap of $14.08 billion, a P/E ratio of 12.19, a P/E/G ratio of 4.64 and a beta of 0.57. The company has a 50 day moving average of $296.44 and a two-hundred day moving average of $307.95. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The company had revenue of $798.60 million during the quarter, compared to analyst estimates of $802.13 million. During the same period in the prior year, the firm posted $5.85 EPS. United Therapeutics's revenue was up 11.7% compared to the same quarter last year. As a group, analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently commented on UTHR shares. Wall Street Zen cut United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 2nd. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of United Therapeutics in a research note on Thursday, August 14th. Morgan Stanley lowered their price objective on shares of United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating for the company in a research report on Thursday, July 10th. JPMorgan Chase & Co. dropped their price target on United Therapeutics from $350.00 to $330.00 and set an "overweight" rating on the stock in a research report on Tuesday, July 8th. Finally, Wells Fargo & Company dropped their price target on United Therapeutics from $314.00 to $295.00 and set an "equal weight" rating on the stock in a research report on Thursday, July 31st. Nine equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, United Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $382.00.

Insider Buying and Selling

In other news, EVP Paul A. Mahon sold 11,000 shares of the stock in a transaction that occurred on Thursday, August 21st. The stock was sold at an average price of $308.75, for a total value of $3,396,250.00. Following the completion of the sale, the executive vice president owned 36,781 shares of the company's stock, valued at approximately $11,356,133.75. This represents a 23.02% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO James Edgemond sold 12,000 shares of the stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $325.37, for a total value of $3,904,440.00. Following the completion of the sale, the chief financial officer directly owned 8,118 shares of the company's stock, valued at approximately $2,641,353.66. The trade was a 59.65% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 92,681 shares of company stock worth $28,014,609. 10.30% of the stock is currently owned by company insiders.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.